Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A systematic review

Journal of Clinical Psychopharmacology

Volumn 28, Issue 2, 2008, Pages 203-209

  Gao, Keming ^a,b   Kemp, David E ^a   Ganocy, Stephen J ^a   Gajwani, Prashant ^a   Xia, Guohua ^a   Calabrese, Joseph R ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PENFURIDOL; PERPHENAZINE; PIMOZIDE; PIPOTIAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; ZIPRASIDONE;

AKATHISIA; BIPOLAR DEPRESSION; BIPOLAR MANIA; CLINICAL TRIAL; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BIPOLAR DISORDER; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TIME FACTORS;

EID: 40949136198     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318166c4d5     Document Type: Review

References (52)

1. Hunt N, Silverstone T. Tardive dyskinesia in bipolar affective disorder: a catchment care study. Int Clin Psychopharmacol. 1991;6:45-50.
2. Hamra BJ, Nasrallah HA, Clancy J, et al. Psychiatric diagnosis and risk for tardive dyskinesia. Arch Gen Psychiatry. 1983;40:346-347.
3. Nasrallah HA, Churchill CM, Hamdan-Allan GA. Higher frequency of neuroleptic-induced dsytonia in mania than in schizophrenia. Am J Psychiatry. 1988;145:1455-1456.
4. Kane JM. Tardive dyskinesia in affective disorders. J Clin Psychiatry. 1999;60(suppl 5):43-47.
5. Khanna R, Das A, Damodaran SS. Prospective study of neuroleptic-induced dystonia in mania and schizophrenia. Am J Psychiatry. 1992;149:511-513.
6. Cavazzoni PA, Berg PH, Kryzhanovskaya LA, et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry. 2006;67:107-113.
7. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414-425.
8. Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry. 2004;65(suppl 9):21-24.
9. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry. 2004;65(suppl 9):16-20.
10. Keepers GA, Casey DE. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry. 1991;148:85-89.
11. Muscettola G, Barbato G, Pampallona S, et al. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol. 1999;19:203-208.
12. Tenback DE, van Harten PN, Slooff CJ, et al. Evidence that early extrapyramidal syndromes predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcome (SOHO) study. Am J Psychiatry. 2006;163:1438-1440.
13. Gao K, Gajwani P, Muzina D, et al. Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry. 2005;66:1376-1385.
14. Gao K, Gajwani P, Muzina D, et al. The effects of antipsychotics on mood. Adv Schizophr Clin Psychiatry. 2006;2:120-127.
15. Bech P, Baastrup PC, de Bleeker E, et al. Dimensionality, responsiveness and standardization of the Bech-Rafaelsen Mania Scale in the ultra-short therapy with antipsychotics in patients with severe manic episodes. Acta Psychiatr Scand. 2001;104:25-30.
16. Samellas D, Read P, Cookson JC. Antipsychotic drugs in mania: factors predicting use of antipsychotic medication following inpatient treatment of mania. Int Clin Psychopharmacol. 2004;19:291-297.
17. McQuay HJ, Moore AR. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126:712-720.
18. Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317:1309-1312.
19. Cumming G, Finch S. Confidence Inference by eye: confidence intervals and how to read pictures of data. Am Psychol. 2005;60:170-180.
20. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763-771.
21. Arvanitis LA, Miller BG, the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry. 1997;42:233-246.
22. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry. 1997;154:782-791.
23. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60:681-690.
24. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blinded olanzapine trial. Neuropsychopharmacology. 1996;14:111-123.
25. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13:25-40.
26. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-835.
27. Keck P Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl). 1998;140:173-184.
28. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999;20:491-505.
29. McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomized, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005;15:573-585.
30. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:1651-1658.
31. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006;20:536-546.
32. Vieta E, Mullen J, Brecher M, et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomized, placebo-controlled studies. Curr Med Res Opin. 2005;21:923-934.
33. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry. 1999;156:702-709.
34. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double blind, placebo-controlled study. Arch Gen Psychiatry. 2000;57:841-849.
35. Smulevich AB, Khanna S, Eerdekens M, et al. Acute and continuation risperidone monotherapy in bipolar mania: a 3-weel placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005;15:75-84.
36. Hirschfeld RMA, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161:1057-1065.
37. Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania. Br J Psychiatry. 2005;187:229-334.
38. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160:741-748.
39. Potkin SG, Keck PE Jr, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005;25:301-310.
40. Marcus RN, Owen R, Swanink R, et al. Two studies to evaluate the safety and efficacy of aripiprazole monotherapy in quetiapine with bipolar I disorder with a major depressive episode without psychotic feature (Studies CN138-096 and CN138-146). In: New Research Abstracts of the 160th Annual Meeting of the American Psychiatric Association; May 19-24, 2007; San Diego, CA. NR 311.
41. Calabrese JR, Keck PE Jr, Macfadden W, et al, for the BOLDER Study Group. A randomized, double-blind, placebo-controlled trial of quetiapine, in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351-1360.
42. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II Study). J Clin Psychopharmacol. 2006;26:600-609.
43. Tohen M, Vieta E, Calabrese JR, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar depression. Arch Gen Psychiatry. 2003;60:1079-1088.
44. Kemp DE, Gilmer WS, Fleck J, et al. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:574-577.
45. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs. haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60:1218-1226.
46. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar disorder. Br J Psychiatry. 2005;187:235-242.
47. Dossenbach M, Arango-Davila C, Ibarra HS, et al. Responses and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study. J Clin Psychiatry. 2005;66:1021-1030.
48. Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998;18:296-304.
49. Kapur S, Remington G, Jones C, et al. High levels of dopamine D2 receptor occupancy with low dose of haloperidol treatment: a PET study. Am J Psychiatry. 1996;153:948-950.
50. Tauscher J, Kufferle B, Asenbaum S, et al. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl). 2002;162:42-49.
51. Ghaemi SN, Hsu DJ, Rosenquist KJ, et al. Extrapyramidal side effects with atypical antipsychotics in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:209-213.
52. Moore RA, Derry S, McQuay HJ. Indirect comparison of interventions using published randomized trials: systematic review of PDE-5 inhibitors for erectile dysfunction. BMC Urol. 2005;5:18.